Gene therapy expert Orchard Therapeutics has teamed up with gene expression engineering Annogen to identify immune cell-specific human promoters for use in some of Orchard's pre-clinical gene therapy programs involving hematopoietic stem cells (HSCs). The terms and financial details of the agreement have not been disclosed.
Annogen's proprietary SuRE™ technology will be used to analyze the human regulatory genome to locate DNA active in different cell types and conditions. The goal is to find the best hybrid promoter to influence gene expression tailored to specific cells or diseases. This collaboration thrusts forward Orchard's HSC gene therapy platform, applying it to more widespread diseases and potentially advancing particular pre-clinical programs.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.